tiprankstipranks
Blurbs

CVS Health (CVS) Receives a Buy from J.P. Morgan

In a report issued on August 3, Lisa Gill from J.P. Morgan maintained a Buy rating on CVS Health (CVSResearch Report), with a price target of $130.00. The company’s shares closed last Thursday at $101.87.

According to TipRanks.com, Gill is a 5-star analyst with an average return of 18.4% and a 66.5% success rate. Gill covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Privia Health Group, and Option Care Health.

CVS Health has an analyst consensus of Moderate Buy, with a price target consensus of $118.10, which is a 15.6% upside from current levels. In a report issued on August 3, Mizuho Securities also reiterated a Buy rating on the stock with a $115.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on CVS Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $76.83 billion and net profit of $2.31 billion. In comparison, last year the company earned revenue of $69.1 billion and had a net profit of $2.22 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.

Read More on CVS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More